Mesenchymal stromal cell therapy compared to SGLT2-inhibitors and usual care in treating diabetic kidney disease: a cost-effectiveness analysis

Luke E. Barry, Grainne E. Crealey, Paul Cockwell, Stephen J. Elliman, Matthew D. Griffin, Alexander P. Maxwell, Timothy O'Brien, Norberto Perico, Ciaran O'Neill*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)
43 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Mesenchymal stromal cell therapy compared to SGLT2-inhibitors and usual care in treating diabetic kidney disease: a cost-effectiveness analysis'. Together they form a unique fingerprint.

Medicine and Dentistry